Literature DB >> 7496785

Non-neural-specific T lymphocytes can orchestrate inflammatory peripheral neuropathy.

G K Harvey1, R Gold, H P Hartung, K V Toyka.   

Abstract

Neural-specific T lymphocytes are held to play a pathological role in inflammatory peripheral nerve disorders such as the Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP). Here, non-neural-specific T-cell-mediated inflammation was studied in peripheral nerves in Lewis rats by systemic transfer of ovalbumin-specific activated T cells followed by intraneural injection of ovalbumin. Rapid endoneurial perivenular infiltration of alpha beta T cells and ED1+ macrophages occurred with ovalbumin injection following transfer of 2 x 10(6) T cells. This cellular infiltration and accumulation produced marked increases in blood-nerve barrier (BNB) permeability. In contrast, control casein injections produced neither significant cell accumulation nor BNB permeability changes. Transfer of a higher number of T cells (5 x 10(6)) induced severe Wallerian degeneration and nerve conduction failure in ovalbumin injected nerves. Fewer T cells (5 x 10(5)) induced conduction block and mild demyelination which were markedly augmented by systemic cotransfer of anti-myelin immunoglobulin. This study demonstrates that activated T cells of non-neural specificity can accumulate in peripheral nerve, produce dramatic changes in BNB permeability and with intravenous anti-myelin antibody orchestrate primary demyelination or axonal degeneration in a dose-dependent fashion.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7496785     DOI: 10.1093/brain/118.5.1263

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  11 in total

Review 1.  Autoimmune responses in peripheral nerve.

Authors:  H P Hartung; H Willison; S Jung; M Pette; K V Toyka; G Giegerich
Journal:  Springer Semin Immunopathol       Date:  1996

Review 2.  The role of apolipoprotein E in Guillain-Barré syndrome and experimental autoimmune neuritis.

Authors:  Hong-liang Zhang; Jiang Wu; Jie Zhu
Journal:  J Biomed Biotechnol       Date:  2010-02-16

Review 3.  [Autoimmune neuropathies--current aspects of immunopathologic diagnostics and therapy].

Authors:  R Gold; A Bayas; K V Toyka
Journal:  Nervenarzt       Date:  2005-08       Impact factor: 1.214

4.  Severe refractory CIDP: a case series of 10 patients treated with bortezomib.

Authors:  Kalliopi Pitarokoili; Min-Suk Yoon; Ilka Kröger; Anke Reinacher-Schick; Ralf Gold; Christiane Schneider-Gold
Journal:  J Neurol       Date:  2017-08-23       Impact factor: 4.849

5.  Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy.

Authors:  E A Marsh; C L Hirst; J G Llewelyn; M D Cossburn; M M Reilly; A Krishnan; M Doran; A M Ryan; A J Coles; J L Jones; N P Robertson
Journal:  J Neurol       Date:  2010-01-06       Impact factor: 4.849

Review 6.  Functional and Structural Changes of the Blood-Nerve-Barrier in Diabetic Neuropathy.

Authors:  Mette Richner; Nelson Ferreira; Anete Dudele; Troels S Jensen; Christian B Vaegter; Nádia P Gonçalves
Journal:  Front Neurosci       Date:  2019-01-14       Impact factor: 4.677

Review 7.  Can antiglycolipid antibodies present in HIV-infected individuals induce immune demyelination?

Authors:  S Petratos; M E Gonzales
Journal:  Neuropathology       Date:  2000-12       Impact factor: 1.906

Review 8.  The Neuroimmunology of Guillain-Barré Syndrome and the Potential Role of an Aging Immune System.

Authors:  Kathleen M Hagen; Shalina S Ousman
Journal:  Front Aging Neurosci       Date:  2021-01-13       Impact factor: 5.750

9.  Role of sensory stimulation in amelioration of obstructive sleep apnea.

Authors:  Mak Adam Daulatzai
Journal:  Sleep Disord       Date:  2011-04-05

10.  Expression of RhoA by inflammatory macrophages and T cells in rat experimental autoimmune neuritis.

Authors:  Zhiren Zhang; Uwe Fauser; Hermann J Schluesener
Journal:  J Cell Mol Med       Date:  2007 Jan-Feb       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.